ARNA Arena Pharmaceuticals, Inc.

1.49
+0  (0%)
Previous Close 1.49
Open 1.51
Price To book 106.43
Market Cap 362.54M
Shares 243,313,000
Volume 981,066
Short Ratio 4.90
Av. Daily Volume 1,638,180

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2017 with data due by the end of 2017.
APD371
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 2 data due by the end of 2017.
APD334
Ulcerative colitis
Phase 2 data due 3Q 2017.
Ralinepag
Pulmonary Arterial Hypertension

Latest News

  1. ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
  2. Arena Pharmaceuticals Appoints Three New Members to Board of Directors
  3. Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017
  4. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 30, 2017
  5. Why Arena Pharmaceuticals Stock Sank in 2016
  6. Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
  7. Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
  8. ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
  9. Arena Pharmaceuticals Dumps Belviq Weight Loss Drug
  10. Genocea Stock Up on Positive Genital Herpes Infections Data
  11. Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
  12. Arena, Eisai Modify Marketing & Supply Agreement for Belviq
  13. Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
  14. Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
  15. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 5, 2017
  16. Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin
  17. ARENA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
  18. Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally
  19. Clovis Declares Pricing of Upsized Offering of Common Stock
  20. Allergan Natrelle Inspira Breast Implants Approved in the U.S.